Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Chiricozzi, A; Talamonti, M; De, Simone, C; Galluzzo, M; Gori, N; Fabbrocini, G; Marzano, AV; Girolomoni, G; Offidani, A; Rossi, MT; Bianchi, L; Cristaudo, A; Fierro, MT; Stingeni, L; Pellacani, G; Argenziano, G; Patrizi, A; Pigatto, P; Romanelli, M; Savoia, P; Rubegni, P; Foti, C; Milanesi, N; Belloni, Fortina, A; Bongiorno, MR; Grieco, T; Di, Nuzzo, S; Fargnoli, MC; Carugno, A; Motolese, A; Rongioletti, F; Amerio, P; Balestri, R; Potenza, C; Micali, G; Patruno, C; Zalaudek, I; Lombardo, M; Feliciani, C; Di, Nardo, L; Guarneri, F; Peris, K, , DA‐COVID‐19, study, group.
Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry.
Allergy. 2021; 76(6):1813-1824 Doi: 10.1111/all.14767 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Co-authors Med Uni Graz: Zalaudek Iris
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: BACKGROUND: Few and small studies have described the management of immunomodulant/immunosuppressive therapies or phototherapy in atopic dermatitis (AD) patients during coronavirus disease 2019 (COVID-19) pandemic. METHODS: A national registry, named DA-COVID-19 and involving 35 Italian dermatology units, was established in order to evaluate the impact of COVID-19 pandemic on the management of adult AD patients treated with systemic immunomodulant/immunosuppressive medications or phototherapy. Demographic and clinical data were obtained at different timepoints by teledermatology during COVID-19 pandemic, when regular visits were not allowed due to sanitary restrictions. Disease severity was assessed by both physician- and patient-reported assessment scores evaluating itch intensity, sleep disturbances, and AD severity. RESULTS: A total of 1831 patients were included, with 1580/1831 (86.3%) continuing therapy during pandemic. Most patients were treated with dupilumab (86.1%, 1576/1831) that was interrupted in only 9.9% (156/1576) of cases, while systemic immunosuppressive compounds were more frequently withdrawn. Treatment interruption was due to decision of the patient, general practitioner, or dermatologist in 39.9% (114/286), 5.6% (16/286), and 30.1% (86/286) of cases, respectively. Fear of increased susceptibility to SARS-CoV-2 infection (24.8%, 71/286) was one of the main causes of interruption. Sixteen patients (0.9%) resulted positive to SARS-CoV-2 infection; 3 of them (0.2%) were hospitalized but no cases of COVID-related death occurred. CONCLUSIONS: Most AD patients continued systemic treatments during COVID pandemic and lockdown period, without high impact on disease control, particularly dupilumab-treated patients.
Find related publications in this database (using NLM MeSH Indexing): Adult - administration & dosage; COVID-19 - administration & dosage; Communicable Disease Control - administration & dosage; Dermatitis, Atopic - drug therapy, epidemiology; Humans - administration & dosage; Italy - epidemiology; Pandemics - administration & dosage; Registries - administration & dosage; SARS-CoV-2 - administration & dosage
Find related publications in this database (Keywords): atopic dermatitis; COVID; SARS-CoV